151 related articles for article (PubMed ID: 38203288)
1.
Bochicchio MT; Marconi G; Baldazzi C; Bandini L; Ruggieri F; Lucchesi A; Agostinelli C; Sabattini E; Orsatti A; Ferrari A; Capirossi G; Servili C; Ghelli Luserna di Rorà A; Martinelli G; Simonetti G; Rosti G
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203288
[No Abstract] [Full Text] [Related]
2. Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.
Xie W; Wang SA; Hu S; Xu J; Medeiros LJ; Tang G
Cancer Genet; 2018 Dec; 228-229():41-46. PubMed ID: 30553471
[TBL] [Abstract][Full Text] [Related]
3. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative Neoplasm Driven by
Renzi S; Algawahmed F; Davidson S; Langenberg KPS; Fuligni F; Ali S; Anderson N; Brunga L; Bartram J; Abdelhaleem M; Naqvi A; Beimnet K; Schuh A; Tierens A; Malkin D; Shlien A; Shago M; Villani A
Curr Oncol; 2023 Jun; 30(7):5946-5952. PubMed ID: 37503586
[No Abstract] [Full Text] [Related]
5. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
[TBL] [Abstract][Full Text] [Related]
6. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
7. Characterization of leukemias with ETV6-ABL1 fusion.
Zaliova M; Moorman AV; Cazzaniga G; Stanulla M; Harvey RC; Roberts KG; Heatley SL; Loh ML; Konopleva M; Chen IM; Zimmermannova O; Schwab C; Smith O; Mozziconacci MJ; Chabannon C; Kim M; Frederik Falkenburg JH; Norton A; Marshall K; Haas OA; Starkova J; Stuchly J; Hunger SP; White D; Mullighan CG; Willman CL; Stary J; Trka J; Zuna J
Haematologica; 2016 Sep; 101(9):1082-93. PubMed ID: 27229714
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review.
Gancheva K; Virchis A; Howard-Reeves J; Cross NC; Brazma D; Grace C; Kotzampaltiris P; Partheniou F; Nacheva E
Mol Cytogenet; 2013 Sep; 6(1):39. PubMed ID: 24053143
[TBL] [Abstract][Full Text] [Related]
9. An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.
Zimmermannova O; Doktorova E; Stuchly J; Kanderova V; Kuzilkova D; Strnad H; Starkova J; Alberich-Jorda M; Falkenburg JHF; Trka J; Petrak J; Zuna J; Zaliova M
Oncogene; 2017 Oct; 36(43):5985-5994. PubMed ID: 28650474
[TBL] [Abstract][Full Text] [Related]
10. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Schwaab J; Naumann N; Luebke J; Jawhar M; Somervaille TCP; Williams MS; Frewin R; Jost PJ; Lichtenegger FS; La Rosée P; Storch N; Haferlach T; Horny HP; Fabarius A; Haferlach C; Burchert A; Hofmann WK; Cross NCP; Hochhaus A; Reiter A; Metzgeroth G
Am J Hematol; 2020 Jul; 95(7):824-833. PubMed ID: 32279331
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.
Xue S; Sun HP; Huang XB; Chen X; Wang T; Ma W; Tian Y; Pan ZL; Li LH; Zhang L; Liu HX; Cao XY
Int J Hematol; 2024 May; 119(5):564-572. PubMed ID: 38441775
[TBL] [Abstract][Full Text] [Related]
12. A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature.
Tirado CA; Siangchin K; Shabsovich DS; Sharifian M; Schiller G
Biomark Res; 2016; 4(1):16. PubMed ID: 27570624
[TBL] [Abstract][Full Text] [Related]
13. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia.
La Starza R; Trubia M; Testoni N; Ottaviani E; Belloni E; Crescenzi B; Martelli M; Flandrin G; Pelicci PG; Mecucci C
Haematologica; 2002 Aug; 87(8):789-94. PubMed ID: 12161353
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing and molecular cytogenetic characterization of ETV6-LYN fusion due to chromosomes 1, 8 and 12 rearrangement in acute myeloid leukemia.
Ma ESK; Wan TSK; Au CH; Ho DN; Ma SY; Ng MHL; Chan TL
Cancer Genet; 2017 Dec; 218-219():15-19. PubMed ID: 29153093
[TBL] [Abstract][Full Text] [Related]
16. An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL.
Kakadia PM; Schmidmaier R; Völkl A; Schneider I; Huk N; Schneider S; Panzner G; Neidel U; Fritz B; Spiekermann K; Bohlander SK
Leuk Res Rep; 2016; 6():50-54. PubMed ID: 27812500
[TBL] [Abstract][Full Text] [Related]
17. Variant of ETV6/ABL1 gene is associated with leukemia phenotype.
Park J; Kim M; Lim J; Kim Y; Han K; Kim JS; Lee S; Kim HJ; Min WS
Acta Haematol; 2013; 129(2):78-82. PubMed ID: 23171811
[TBL] [Abstract][Full Text] [Related]
18. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
20. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
